glp-1 ลดน้ําหนัก คืออะไร ? ช่วยคุมหิว ลดน้ำหนักได้จริงไหม ปลอดภัยหรือไม่ ยากลุ่มGLP1มีผลต่อLeanMassหรือไม่มากน้อยเพียงใด?​ #งานวิจัยใหม่ล่าสุดมีคำตอบให้ 👨‍⚕️📝🚩 หนึ่งในคำถามสำคัญของการรักษาโรคอ้วน (obesity)

Always double-check the most current FDA label or corporate press release indications, titrations, and payer coverage are changing rapidly.) FDA-Approved Medications and Indications (As of Fall 2025) Lets start with a quick rundown of the major players Ozempic, Wegovy, Mounjaro, and Zepbound and what theyre actually approved to treat: Ozempic (semaglutide injection) Type 2 diabetes mellitus, adjunct to diet and exercise To reduce major adverse cardiovascular events (MACE: Cardiovascular death, nonfatal myocardial infarction, stroke) in adults with Type 2 diabetes mellitus and established cardiovascular disease Approved (Jan 2025) to reduce the risk of chronic kidney disease progression and cardiovascular death in Type 2 Diabetes mellitus and chronic kidney disease Rybelsus (oral semaglutide) Type 2 Diabetes mellitus, adjunct to diet and exercise To reduce major adverse cardiovascular events (MACE: Cardiovascular death, nonfatal myocardial infarction, stroke) in patients with Type 2 Diabetes at high risk for MACE Mounjaro (tirzepatide injection) Type 2 Diabetes mellitus, adjunct to diet and exercise No current FDA indication for weight loss or cardiovascular disease prevention (though trials are ongoing) Wegovy (semaglutide injection, higher max dose for weight loss) Chronic weight management in: - Adults with obesity (BMI 30) - Adults with overweight (BMI 27) plus at least one weight-related comorbidity To reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease Recently approved for noncirrhotic metabolic-associated steatohepatitis (with F2F3 fibrosis) in adults Zepbound (tirzepatide for weight loss) Chronic weight management in adults with obesity or overweight, plus at least one comorbidity Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity Insurance Coverage Realities Even when the indications are met, insurance coverage for GLP-1s isnt guaranteed

Why have GLP-1 receptors historically been difficult to target with small molecules, and what has changed to make oral versions possible now

Interestingly, GLP-1RA treatment is associated with small reductions in systolic blood pressure, which seem independent of GLP-1RA-induced weight loss (34)

A weight loss 5% occurred in 54.3, 40.4, and 21.4% of patients, respectively, and a weight loss 10% occurred in 25.2, 15.9, and 6.7% of patients, respectively

Microdosing is often being explored by women who are somewhat metabolically flexible, not seeking major weight loss, and interested in using these drugs more like a supplement but thats where things get complicated

Nadolsky shares he often gets backlash for his take on the question: is obesity a choice